Madrigal Pharmaceuticals Reports 71% Revenue Growth to $364.3 Million in Q2 2026

Madrigal Pharmaceuticals, Inc. reported significant financial results for the second quarter of 2026, with product revenue reaching $364.3 million, a 71% increase from $212.8 million in the same period last year. For the first half of 2026, total revenue was $675.6 million, up 93% from $350.1 million in the first half of 2025. Despite this growth, the company recorded a net loss of $57.9 million for the quarter, compared to a loss of $42.3 million in the prior year, reflecting increased operating expenses driven by commercialization efforts and research and development activities.

Operating expenses for the second quarter totaled $420.6 million, a 62% increase from $260.0 million in the same quarter of 2025. This rise was primarily attributed to a 341% increase in cost of sales, which amounted to $40.0 million, largely due to higher royalties payable to Roche and a $10.4 million write-down of work-in-process inventory. Research and development expenses also surged by 69% to $91.2 million, influenced by one-time business development costs and increased personnel expenses related to pipeline expansion. Selling, general, and administrative expenses rose 47% to $289.4 million, driven by investments in marketing and an expanded workforce.

Madrigal's operational developments included the continued commercialization of its product, Rezdiffra, which was approved by the FDA in March 2024 and launched in the U.S. in April 2024. The company also expanded its market presence in Europe, launching Rezdiffra in Germany in September 2025. As of June 30, 2026, Madrigal had cash, cash equivalents, and marketable securities totaling $838.9 million, down from $988.6 million at the end of 2025, indicating a strong liquidity position to support ongoing operations and development.

Looking ahead, Madrigal anticipates continued investment in its product pipeline and commercialization efforts. The company is focused on expanding the indications for Rezdiffra and is conducting ongoing clinical trials, including the MAESTRO-NASH OUTCOMES trial, which could broaden the patient population eligible for treatment. Management expects to incur losses until sufficient revenue is generated from Rezdiffra and other potential products, but believes its current cash reserves will sustain operations for at least the next year. The company may seek additional capital through equity or debt financing to support its long-term growth strategy.